Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
OncoC4, Inc.
Pfizer
USWM, LLC (dba US WorldMeds)
Seagen Inc.
KaliVir Immunotherapeutics
Pfizer
M.D. Anderson Cancer Center
Pfizer
Bayer
iOnctura
Sotio Biotech Inc.
Pfizer
Pfizer
National Cancer Institute (NCI)
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Bayer
Mayo Clinic
Dragonfly Therapeutics
Dragonfly Therapeutics
Stanford University
Merck Sharp & Dohme LLC
Fred Hutchinson Cancer Center
Emory University
Deciphera Pharmaceuticals, LLC
ViroMissile, Inc.
Erasca, Inc.
Pfizer
Tizona Therapeutics, Inc
Boehringer Ingelheim
Shanghai Henlius Biotech
MacroGenics
Hefei TG ImmunoPharma Co., Ltd.
City of Hope Medical Center
Novartis
AbbVie
AgonOx, Inc.
Innate Pharma
Novartis
Pierre Fabre Medicament
Amgen
Kezar Life Sciences, Inc.
Compass Therapeutics
Degron Therapeutics Co.
University Health Network, Toronto